A cross-sectional study found the prevalence of idiopathic intracranial hypertension among women in the United States varied ...

Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...

Ramreddy Meka's insights shed light on a future where technology not only sustains but significantly enhances the quality of ...

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

Greetings. Welcome to Mineralys third-quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce Dan ...

Professor Martin Tamatey, a heart surgeon and Acting Director of the National Cardiothoracic Center at Korle-Bu Teaching ...

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report). The ...

Researchers at Helix found that an integrated polygenic risk score with co-morbid factors such as the presence of type 2 diabetes and hypertension could predict ... we are generating insights that ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...

The Australian Cardiovascular Alliance (ACvA) has received vital Federal funding to advance its innovative national approach addressing cardiovascular ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...